BioGaia Pharma AB
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.biogaiapharma.com
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
Phase 2
Recruiting
- Conditions
- Opioid-Induced Constipation
- Interventions
- Biological: Lactobacillus gasseri BGP345ABiological: Placebo
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- BioGaia Pharma AB
- Target Recruit Count
- 126
- Registration Number
- NCT05133076
- Locations
- 🇫🇷
CHU DE NANTES (Hôpital Nord Laennec), Saint- Herblain, France
🇫🇷CH de Valenciennes, Valenciennes, France
🇫🇷CHU d'Amiens, Amiens, France
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
Phase 1
Recruiting
- Conditions
- Ulcerative Colitis
- Interventions
- Biological: BGP-014Biological: Placebo
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- BioGaia Pharma AB
- Target Recruit Count
- 50
- Registration Number
- NCT05118919
- Locations
- 🇸🇪
Gastroenterology Department, Ersta Hospital, Stockholm, Sweden
🇸🇪Gastroenterology Department, Danderyds Hospital, Stockholm, Sweden
🇸🇪Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital, Uppsala, Sweden
© Copyright 2025. All Rights Reserved by MedPath